Unlocking the potential of these models, which could revolutionize the utility and power of NHP models of HIV-1 infection, will require the development of a mmHIV-1 capable of establishing a pathogenic infection course characterized by sustained, elevated plasma viral loads, progressive CD4+ T-cell loss, and the development of AIDS-defining clinical endpoints. The gene discussed is CD4; the disease is infection.